There is evidence that in ovarian cancer, the enzyme indoleamine 2,3-dioxygenase (IDO) catalyzes the breakdown of tryptophan through the kynurenine pathway, resulting in immunosuppressive compounds that accelerate the growth of tumor cells and reduce antitumor immunity (109, 110). This evidence concerns the gene IDO1 and ovarian carcinoma.